TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04238806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Inhalational agent
Description: Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Inhalational agent
Description: Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
Study: NCT01060293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose furosemide
Description: High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose furosemide
Description: Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose furosemide combined with low-dose dopamine
Description: Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
Study: NCT03731468

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: local anesthetic
Description: ultrasound guided superficial cervical block in thyroid surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone will be added to ultrasound guided superficial cervical block in thyroid surgery
Study: NCT01347333

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic body radiosurgery
Description: 36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: 26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
Study: NCT01708850

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: All specified in arm description. One arm study.
Study: NCT03691467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate dental implant
Description: immediate dental implant placement in freshly extracted socket.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate dental implant
Description: immediate dental implant placement in freshly extracted socket.
Study: NCT00631670

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 15 Gy in one treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Dose: 70 Gy at 2.8 Gy/treatment
Study: NCT04008342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory intervention
Description: The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
Study: NCT02325700

Intervention type: PROCEDURE
Intervention: Aortic repair
Description: Aortic bypass

Intervention type: PROCEDURE
Intervention: Aortic repair
Description: Aortic bypass
Study: NCT00551564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: Rosiglitazone tablets 4 mg dose will be administered orally by subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: Rosiglitazone tablets 4 mg dose will be administered orally by subjects
Study: NCT04558216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: 20 mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg (Two 300 mg capsules)
Study: NCT02203136

Intervention type: PROCEDURE
Intervention: Tissue Biopsy
Description: During bladder cancer surgery, tissue specimen taken for molecular profiling.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
Study: NCT03691467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: topical application of hyaluronic acid
Study: NCT00639873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: 2 or 4 mg/kg/day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: 2 or 4 mg/kg/day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinine-doxycycline
Description: quinine-doxycycline for 7 days
Study: NCT02866890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction
Description: Laryngeal Tube Suction Measurement of leak pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction
Description: Laryngeal Tube Suction Measurement of leak pressure
Study: NCT03717766

Intervention type: DEVICE
Intervention: intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology
Description: 5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity
Study: NCT02866890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction
Description: Laryngeal Tube Suction Measurement of leak pressure
Study: NCT00961090

Intervention type: DRUG
Group type: OTHER
Intervention: Aminolevulinic Acid
Description: 20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
Study: NCT03973619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Labial Graft
Description: As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jugal Graft
Description: As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
Study: NCT03882333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: 30 min acute exercise (bicycle at stationary cycle)
Study: NCT03602131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg oral twice weekly for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 6 mg/m2 intravenously once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 mg/m2 intravenously twice weekly for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg intravenously once daily for 4 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
Study: NCT02844946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
Study: NCT06061510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids
Description: Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
Study: NCT03640260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing regulation with physical activity
Description: The subjects will have education leaflets with breathing and oximetry level evaluation training.
Study: NCT02071004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: IV of 6 mg given once over 30 minutes
Study: NCT02710578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
Study: NCT01808144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad
Description: Tablets, 400 mg once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad
Description: Tablets, 200 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: Tabletsm 80 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: Tabletsm 80 mg QD
Study: NCT01138098

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular, single dose
Study: NCT01919255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolight + Coolprep
Description: Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolight + Coolprep
Description: Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolight + Clicolon
Description: Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolight + Clicolon
Description: Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
Study: NCT00068718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV
Study: NCT01398345

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Respiratory Training
Description: Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
Study: NCT03119532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receive metric feedback email
Description: If the provider received an email about the participants performance metrics
Study: NCT01785784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF Gel
Study: NCT01104857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diaphragm muscle biopsy
Description: Biopsy is obtained for biochemical analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm muscle biopsy
Description: Biopsy is obtained for biochemical analysis
Study: NCT03591978

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of Circulating Pulmonary Cells in peripheral blood
Description: Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of Circulating Pulmonary Cells in peripheral blood
Description: Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of Circulating Pulmonary Cells in peripheral blood
Description: Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
Study: NCT00289458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2
Description: Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: no exercise
Study: NCT03360201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuko Pamoja, We are Together in Kiswahili
Description: Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context.
Study: NCT03158259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehospital diagnosis and treatment
Description: The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehospital diagnosis and treatment
Description: The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
Study: NCT00782002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-18F1
Description: Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
Study: NCT02071004

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Dispersible tablet, 300mg \& 75 mg, once daily for 5 days
Study: NCT01210391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey infant formula
Description: New hydrolyzed infant formula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolyzed casein infant formula
Description: Commercially available infant formula.
Study: NCT01016769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus + Weekly Paclitaxel + Carboplatin
Description: Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.~Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week.
Study: NCT00344786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNF2024 (BIIB021)
Description: Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment.
Study: NCT03788837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILOPROST
Description: The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
Study: NCT01189916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopically assisted Appendectomy Surgery
Description: Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
Study: NCT01015391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2
Description: 1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
Study: NCT04528511

Intervention type: DEVICE
Intervention: Continuous Electronic Monitor
Description: All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden

Intervention type: DEVICE
Intervention: Continuous Electronic Monitor
Description: All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
Study: NCT00960466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problems List
Description: When using the distress thermometer and problem list (DT\&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT\&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual psychosocial support
Description: If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
Study: NCT02650648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight\<70kg) or 1500mg/m\^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10\^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu3F8
Description: On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over \~30-90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rIL-2
Description: On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10\^5 U/m\^2/day.